

ASCERTAIN CONSORTIUM GATHERS IN OSLO TO ADVANCE FAIR ACCESS TO INNOVATIVE HEALTH TECHNOLOGIES

Oslo, June 30, 2025 –The ASCERTAIN Consortium held its Stakeholder Day in Oslo, bringing together experts from academia, healthcare, industry, and policy to discuss strategies for sustainable, equitable access to innovative health technologies (IHTs). The meeting focused on refining ASCERTAIN’s access-based pricing, cost-effectiveness, and reimbursement models to better meet stakeholder needs.

Opening the day, Carin Uyl-de Groot (Erasmus University Rotterdam), project coordinator, outlined ASCERTAIN’s mission: to develop a publicly accessible, cloud-based policy support tool to improve equitable access to IHTs across Europe. She highlighted financial pressures on healthcare systems, persistent access disparities between EU states, uncertainty in clinical evidence, and the environmental impact of medical products. Work focuses on three use cases: Precision Cancer Medicine, Cell and Gene Therapy (e.g., CAR T-cells), and Next Generation Sequencing.

In the morning, Maximilian Salcher-Konrad (Gesundheit Österreich) and Anne Hendrickx (AIM) presented a formula-based pricing model combining cost-based factors (R&D, manufacturing) with value-based components (therapeutic benefit, societal value). Adaptable to EU contexts, it complements national systems. An oncology example showed how disease prevalence can affect final prices. Stakeholders contributed diverse perspectives. The European Association of Hospital Pharmacists called for transparent pricing and procurement tools; IKK e.V. proposed using the model for benchmark prices in Germany’s AMNOG process. The European Hematology Association cited the affordability crisis and delays from price disputes.

In the afternoon, Eline Aas (University of Oslo) introduced open-source cost-effectiveness models for technical experts and decision-makers, adaptable to local needs. Tom Belleman (Erasmus University Rotterdam) outlined reimbursement modeling for Managed Entry Agreements (MEAs) linking payment to real-world outcomes. Operational insights from AbbVie Scandinavia, NoMA, and Sykehusinnkjøp emphasized transparency, adaptability, and evidence-based updates. The day closed with the ASCERTAIN Policy Support Tool presentation, offering guided workflows, AI support, parameter validation, and secure sharing.

For more information, visit www.access2meds.eu. About ASCERTAIN: www.access2meds.eu

Press contact

Name: Prof.dr Carin Uyl-de Groot

Position: Professor of Health Technology Assessment and Director of the Institute for Medical Technology Assessment (iMTA), Project coordinator of the Horizon Europe project ASCERTAIN Erasmus School of Health Policy & Management (ESHPM)

Erasmus University of Rotterdam

E-Mail: uyld@eshpm.eur.nl